Technology Appraisal Guidance No. 185
Source: National Institute for Health and Care Excellence
1.1 Trabectedin is recommended as a treatment option for people with advanced soft tissue sarcoma if:
- treatment with anthracyclines and ifosfamide has failed or
- they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide
- the acquisition cost of trabectedin for treatment needed after the fifth cycle is met by the manufacturer.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at
An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by ing 0845 003 7783 or emailingand quoting reference number N2104. It is also available on the Internet at
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:
Trabectedin for the treatment of advanced soft tissue sarcoma
Issue Date: February 2010
Review Date: February 2013